Sensory gating and P50: Neurobiology implications for schizophrenia;Filtrado sensorial y P50: Implicaciones para la neurobiología de la esquizofrenia

Salud Mental

Volumn 29, Issue 1, 2006, Pages 64-70

  García Anaya, María ^a   Apiquian, Rogelio ^b   Fresán, Ana ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

P50; Schizophrenia; Sensory gating

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; ADENOSINE; ALPHA 7 NICOTINIC RECEPTOR; DOPAMINE; NEUROLEPTIC AGENT; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

AUDITORY STIMULATION; DRUG MECHANISM; ELECTRODE; ELECTROENCEPHALOGRAM; EVENT RELATED POTENTIAL; EVOKED RESPONSE; HIPPOCAMPUS; HUMAN; MENTAL DISEASE; PATHOPHYSIOLOGY; PSYCHOPHARMACOLOGY; PYRAMIDAL NERVE CELL; REVIEW; SCHIZOPHRENIA; SENSORY STIMULATION; TEMPORAL LOBE;

EID: 33645729898     PISSN: 01853325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. ADLER L, PACHTMAN E, FRANKS R, PECEVICH M y cols.: Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry, 17:639-654, 1982.
2. ADLER L, HOFFER LJ, GRIFFITH J, WALDO M y cols: Normalization by nicotine of deficit auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry, 32:607-616, 1992.
3. ADLER L, HOFFER L, WISER A, FREEDMAN R: Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry, 150(12):1856-1861, 1993.
4. ADLER LE, OLINCY A, WALDO M, HARRIS JG y cols: Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull, 24(2):189-202, 1998.
5. ADLER LE, CAWTHRA E, NAGAMOTO HT, OLINCY A y cols: Confirmation of differing distribution of P50 ratios in schizophrenic patients versus controls. Biol Psychiatry, 47:35S, 2000.
6. AKBARIAN SV, VINUELA A, KIM JJ, POTKIN SG y cols: Distorted distribution of nicotiamide-adenine dinuclotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry, 50:178-187, 1993.
7. ARANGO C, SUMMERFELT A, BUCHANAN RW: Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry, 160:2066-2068, 2003.
8. BECKER J, GOMES I, GHISOLFI ES, SCHUCH A y cols: Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia. Clin Neurophysiol, 115:396-401, 2004.
9. BERGER F, GAGE FH, VIJAYARAGHAVAN S: Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J Neurosci, 18:6871-81, 1998.
10. BRAFF D, JUDD L: Regional erp/attention deficits in schizophrenia. Soc Biol Psychiatry Abstr, 109, 1987.
11. BRAFF DL, GEYER MA: Sensorimotor gating and schizophrenia: Human and animal model studies. Arch Gen Psychiatry, 47:181-188, 1990.
12. BRAMON E, RABE-HESKETH S, SHAM P, MURRAY RM y cols: Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res, artículo en prensa.
13. CARDENAS VA, GERSON J, FEIN G: The reliability of P50 suppression as measures by the conditioning/testing ratio is vastly improved by dipole modeling. Biol Psichiatry, 33:335-344, 1993.
14. CLEMENTZ BA, GEYER MA, BRAFF DL: P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry, 41:1035-1044, 1997.
15. CLEMENTZ BA, GEYER MA, BRAFF DL: Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry, 155:1691-1694, 1998.
16. ERWIN RJ, BUCHWALD JS: Midlatency auitory evoked responses: Differential recovery cycle characteristics. Electroencephalogr Clin Neurophysiol, 64:417-423, 1986.
17. FIKENZELLER P, KEIDEL WD: Correlates of auditory perception in averaged prestimulatory EEG-DC recordings. En: Quantitative Analysis of the EEG. Methods and Applications. AEG- Telefunken, 1975.
18. FREEDMAN R, ADLER LE, WALDO MC, PACHTMAN E y cols: Neurophysical evidence for a defect in inhibitory pathways in schizophrenia: Comparison of medicated and drug-free patients. Biol Psychiatry, 18(5):537-551, 1983.
19. FREEDMAN R, ADLER LE, BAKER N, ROSE G y cols: Noradrenergic and dopaminergic modulation of auditory evoked potentials in schizophrenia and mania. American College of Neuropsychopharmacology, 25th Annual Meeting, pp. 147, 1986.
20. FREEDMAN R, ADLER LE, GERHARDT GA, WALDO MC y cols: Neurobiological studies of sensory gating in schizophrenia. Schizophr Bull, 13:669-678, 1987.
21. FREEDMAN R, WETMORE C, STROMBERG I, LEONARD S y cols: Alpha-bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth factor expression. J Neurosci, 13:1965-1975, 1993.
22. FREEDMAN R, HALL M, ADLER LE, LEONARD S: Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol psychiatry, 38:22-33, 1995.
23. FREEDMAN R, COON H, MYLES-WORSLEY M, ORR-URTREGER A y cols.: Linkage of a neuropshysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA, 94:587-592, 1997.
24. FREEDMAN R, ADLER LE, LEONARD S: Alternative phenotypes for the complex genetics of schizophrenia. Biol Psychiatry, 45:551-558, 1999.
25. FREEDMAN R, ADAMS CE, LEONARD S. The a7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanatomy, 20:299-306, 2000.
26. FRUHSTORFER H, SOVERI P, JARVILEHTO T: Short-term habituation of the auditory ecoked response in man. Electroencephalogr Clin Neurophysiol, 28:153-159, 1970.
27. GHISOLFI ES, PROKOPIUK AS, BECKER J, EHLERS JA y cols: The adenosine antagonist theophylline impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacol, 27(4):629-637, 2002.
28. GOFF WR, WILLIAMSON PD, VAN GILDER JC, ALLISON T y cols.: Neural origins of long latency evoked potentials recorded from the depth and from the cortical surface of the brain in man. Prog Clin Nuerophysiol, 7:126-145, 1980.
29. GOTTESMAN II, GOULD TD: The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry, 160:1-10, 2003.
30. HAROUTUNIAN V, DAVIDSON M, KANOF PD, PERL DP y cols.: Cortical cholinergic markers in schizophrenia. Schizophr Res, 12:137-44, 1994.
31. HERSHMAN K, FREEDMAN R, BICKFORD PC: GABAB antagonists diminish the inhibitory gating of auditory response in the rat hippocampus. Neurosci Lett, 190:133-136, 1993.
32. JOHNSON MR, ADLER LE: Transient impairment in P50 auditory sensory gating induced by a cold-pressor test. Biol Psychiatry, 33(5):380-387, 1993.
33. JUDD LL, MCADAMS LA, BUDNICK B, BRAFF DL: Sensory gating deficits in schizophrenia: New results. Am J Psychiatry, 149:488-492, 1992.
34. KATHMAN N, ENGEL RR: Sensory Gating in normals and schizophrenics: a failure to find strong P50 suppression in normals. Biol Psychiatry, 27:1216-1226, 1990.
35. KOMURO H, RAKIC P. Intracellular Ca2+ fluctuations modulate the rate of neuronal migration. Neuron, 17:275-85.
36. LEONARD S, GAULT J, HOPKINS J, LOGEL J y cols.: Association of Promoter Variants in the a7 Nicotinic Acetylcholine Receptor Subunit Gene With an Inhibitory Deficit Found in Schizophrenia. Arch Gen Psychiatry, 59:1085-1096, 2002.
37. LIGHT GA, GEYER MA, CLEMENTZ BA, CADENHEAD KS, BRAFF DL: Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry, 157(5):767-771, 2000.
38. LINDSEY DF, ADEY WR: Avalibility of peripheral input to the midbrain reticular formation. Exp Neurol, 4:358, 1961.
39. MARTIN LF, WILLIAM K, FREEDMAN R: Alpha-7 nicotinic receptors agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacol, 174:54-64, 2004.
40. MCGHIE A, CHAPMAN J: Disorders of attention in early schizophrenia. Br J Med Psychol, 34:103-116, 1961.
41. MYLES-WORSLEY M, ORD L, BLAILES F, NGIRALMAU H, FREEDMAN R: P50 sensory gating in adolescents from a Pacific Island Isolate with elevated risk for schizophrenia. Biol Psychiatry, 55:663-667, 2004.
42. NAGAMOTO H, ADLER LE, WALDO MC, FREEDMAN R: Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol Psychiatry, 25:549-561, 1989.
43. NAGAMOTO HT, ADLER LE, HEA RA, GRIFFITH JM y cols.: Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry, 40(3):181-188, 1996.
44. NAGAMOTO HT, ADLER LE, MCRAE KA, HUETTL P y cols.: Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenyglycol. Neuropsychobiology, 39(1):10-17, 1999.
45. PATTERSON JV, JUN Y, GIERCZAK M, HETRICK WP y cols.: Effects of temporal variability on P50 and the gating ratio in schizophrenia: a frequency domain adaptive filter single-trial analysis. Arch Gen Psychiatry, 57(1):57-64, 2000.
46. POMPER MG, WEBSTER M, BOBO LD: Hippocampal a7 nicotinic cholinergic receptor, neuronal nitric oxide synthase, and glutamic acid decarboxylase mRNA co-localization in schizophrenia. Schizophr Res, 36:75-85, 1999.
47. REITE M, TEALE P, ZIMMERMAN J, DAVIS K y cols.: Source origin of a 50-msec latency auditory evoked field component in young schizophrenic men. Biol Psychiatry, 24(5):495-506, 1988.
48. RIVERA J: Interpretación del MMPI en la Psicología Clínica, Laboral y Educativa. Ed. Manual Moderno. México, 1991.
49. ROTH WT, KOPEL BS: The auditory evoked response to repeated stimuli during a vigilance task. Psychophysiology, 6:301-309, 1969.
50. SCHWARTZ M, SHAGASS C: Reticular modification of somatosensory cortical recovery function. Electroencephalogr Clin Neurophysiol, 15:265-271, 1963.
51. SIDDLE DA: Orienting, habituation, and resource allocation: an associative analysis. Psychophysiology, 28:245-259, 1991.
52. SIEGEL C, WALDO MC, MIZNER G, ADLER LE, FREEDMAN R: Deficits in sensory gating in schizophrenic patients and their relatives. Arch Gen Psychiatry, 41:607-612, 1984.
53. VENABLES PH: Input dysfunction in schizophrenia. Prog Exp Pers Res, 72:1-47, 1964.
54. WALDO MC, CAREY G, MYLES-WORSLEY M, CAWTHRA E y cols.: Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res, 39:257-268, 1991.
55. WARD MM, MEFFORD IN, PARKER SD: Epinephrine and norepinephrine responses in continously collected human plasma to a series of Stressors. Psychosom Med, 45(6):471-486, 1983.
56. WILSON CL, BABB TL, HALGREN E, WANG ML, CRANDALL PH: Habituation of human limbic neuronal response to sensory stimulation. Exp Neurol, 84:74-97, 1984.